Please use this identifier to cite or link to this item:
|Title:||Vasopressin receptor antagonism--a therapeutic option in heart failure and hypertension.||Austin Authors:||Burrell, Louise M ;Risvanis, John;Johnston, Colin I;Naitoh, M;Balding, Leanne C||Affiliation:||Department of Medicine, University of Melbourne, Austin and Repatriation Medical Centre, Heidelberg, Victoria, Australia||Issue Date:||1-Mar-2000||Publication information:||Experimental Physiology; 85 Spec No(): 259S-265S||Abstract:||The precise role of vasopressin in the pathophysiology of cardiovascular disease is controversial, but this peptide hormone is important for several reasons. Firstly, circulating concentrations of vasopressin are elevated in heart failure and some forms of hypertension. Secondly, there is evidence that vasopressin is synthesized not only in the hypophysial-pituitary axis but also in peripheral tissues including the heart where it acts as a paracrine hormone. Thirdly, vasopressin has vasoconstrictor, mitogenic, hyperplastic and renal fluid retaining properties which, by analogy with angiotensin II, may have deleterious effects when present in chronic excess. Finally, the availability of orally active non-peptide vasopressin receptor antagonists allows vasopressin receptor antagonism to be considered as a therapeutic option in cardiovascular disease.||Gov't Doc #:||10795930||URI:||http://ahro.austin.org.au/austinjspui/handle/1/9225||URL:||https://pubmed.ncbi.nlm.nih.gov/10795930||Type:||Journal Article||Subjects:||Antidiuretic Hormone Receptor Antagonists
Heart Failure.drug therapy.physiopathology
Spiro Compounds.therapeutic use
|Appears in Collections:||Journal articles|
Show full item record
checked on Dec 2, 2022
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.